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Abstract:  After  ingestion  via  contaminated  food  or  water,  enterohaemorrhagic  E.  coli 
colonises the intestinal mucosa and produces Shiga toxins (Stx). No Stx-specific secretion 
system has been described so far, and it is assumed that Stx are released into the gut lumen 
after bacterial lysis. Human intestinal epithelium does not express the Stx receptor Gb3 or 
other Stx binding sites, and it remains unknown how Stx cross the intestinal epithelial 
barrier  and  gain  access  to  the  systemic  circulation.  This  review  summarises  current 
knowledge about the influence of the intestinal environment on Stx production and release, 
Stx  interaction  with  intestinal  epithelial  cells  and  intracellular  uptake,  and  toxin 
translocation into underlying tissues. Furthermore, it highlights gaps in understanding that 
need to be addressed by future research. 
Keywords:  Shiga toxin; human intestinal epithelium; regulation; intracellular transport; 
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1. Introduction 
Enterohaemorrhagic E. coli (EHEC) is a major foodborne bacterial pathogen which is responsible 
for around 1200 cases of gastroenteritis per year in the UK. Although this constitutes only 1–3% of 
laboratory cases of food poisoning, EHEC infections can lead to severe systemic complications such as 
haemorrhagic colitis and haemolytic uraemic syndrome (HUS) which can be fatal [1]. Young children 
and the elderly are particularly at risk, and HUS is the leading cause of acute kidney failure in children 
in the developed world. At present, there is no specific treatment for HUS, and use of antibiotics 
remains controversial [2]. HUS is associated with the production of bacterial Shiga toxins (Stx) which 
are highly cytotoxic to renal microvascular endothelium [3,4]. The glycolipid globotriaosylceramide 
(Gb3) has been identified as Stx receptor [5]. 
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2. Regulation of Stx Production and Release 
Shiga toxins from EHEC can be divided into two types, Stx1 and Stx2, which are antigenically 
different  but  have  the  same  mode  of  action  [6].  Stx  are  encoded  by  the  late  genes  of  lambdoid 
prophages integrated in the bacterial chromosome. Three promotors located upstream of the stx genes 
have been identified: one stx-specific promoter (pstx) and two phage promotors (pR, pR’) (reviewed in 
[7]). Previous studies suggest that stx1 and stx2 transcription are regulated differently. 
2.1. Iron 
In most Stx1-producing EHEC strains, stx1 genes are transcribed from pstx1 which is induced under 
low iron concentrations by release of Fur-mediated repression [8]. As transcription from pstx1 does not 
involve  expression  of  the  late  phage  lysis  genes,  induction  of  stx1  expression  does  not  result  in 
bacterial  lysis  and  Stx1  remains  within  the  bacterial  cell  where  it  mainly  localises  in  the  
periplasm [9–11]. 
2.2. Phage Lytic Cycle 
In contrast to stx1, transcription of stx2 genes is highly dependent on induction of the phage lytic 
cycle as it is mainly governed by the late phage promoter pR’ [12]. As a result, stx2 expression is 
induced by DNA-damaging agents, such as UV radiation, mitomycin C and certain antibiotics, the use 
of which is contraindicated during EHEC infection because of enhanced Stx production [9,13,14]. 
DNA  damage  results  in  a  bacterial  SOS  response  and  activation  of  RecA  which  in  turn  leads  to 
autocleavage of the phage repressor cI and initiates sequential transcription of early and late phage 
genes. Early genes are responsible for replication of the phage genome thereby increasing the number 
of stx2 gene copies within the bacterial cell. Expression of late genes  leads to production of Stx, 
bacterial lysis and toxin release [15,16]. The strong association between stx2 expression and the phage 
lytic cycle likely explains why Stx2 is mainly found in supernatants rather than lysates of bacterial 
cultures [6,10,17]. Increased release of Stx2 compared with Stx1 might contribute to the high HUS risk 
that has been associated with Stx2-producing EHEC [18,19]: as EHEC are non-invasive and do not 
cross the intestinal epithelium and cause systemic infection, it is likely that HUS is caused by Stx 
released into the gut lumen which subsequently gets access to the bloodstream. 
2.3. Outer Membrane Vesicles 
So far, no bacterial secretion system has been identified for Stx, and phage-induced bacterial lysis is 
assumed to be the main mechanism of toxin release into the environment. However, outer membrane 
vesicles (OMV), which are naturally shed from the outer membrane of gram-negative bacteria, are 
gaining increased recognition as delivery vehicles for bacterial virulence factors and toxins (reviewed 
by [20,21]). Interestingly, it has been demonstrated that OMV from EHEC broth cultures contain Stx1 
and Stx2 [22,23]. OMV are formed during bacterial infection and can be internalised by eukaryotic 
cells  as  has  been  reported  for  toxin  delivery  by  enterotoxigenic  E.  coli  [24].  It  remains  to  be 
investigated  whether  Stx  release  in  OMV  plays  a  relevant  role  in  Stx  delivery  across  intestinal 
epithelium and development of HUS. Toxins 2011, 3                                      
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2.4. Intestinal Environment 
Regulation of Stx expression has been investigated extensively in bacterial broth cultures but it 
remains unknown how toxin production is regulated in the complex environment of the human gut. 
Prominent features of the intestinal milieu include low oxygen levels, the presence of a mucus layer 
with commensal microflora, and polarised intestinal epithelial cells (IEC). 
2.4.1. Oxygen 
Studies on the influence of oxygen levels on bacterial virulence gene expression are rare but have 
recently  gained  increased  attention  as  the  involvement  of  global  regulators  of  metabolism  in 
pathogenesis  is  becoming  more  evident  (reviewed  in  [25]).  In  the  case  of  EHEC,  studies  on  
steady-state chemostat cultures have demonstrated that low oxygen levels per se do not affect Stx1 or 
Stx2 production but lead to increased EHEC host cell adherence [26]. It can be speculated that the 
latter indirectly leads to higher Stx levels in the gut but this needs to be studied in appropriate infection 
models. 
2.4.2. Microbiota 
Infections in mice and in vitro studies have demonstrated an inhibitory effect of probiotic bacteria, 
such as Lactobacillus and Bifidobacterium, on Stx1 and Stx2 production, and this has been attributed 
to low pH caused by high levels of acetate production by these bacteria [27,28]. Similarly, secreted 
factors from human microbiota, in particular from predominant Bacteroides thetaiotamicron, inhibit 
Stx2 production by repression of the phage lytic cyle [29]. The importance of the microflora on Stx 
levels in the gut is further underlined by a study showing that Stx2 phage infection of susceptible 
commensal  E. coli leads  to  increased Stx2 production [30]. Interestingly, subsequent  screening of 
human intestinal E. coli isolates revealed that most strains were resistant to phage infection. However, 
the rate of about 10% of susceptible isolates corresponds remarkably well with the HUS risk associated 
with EHEC infection, leading to the hypothesis that HUS susceptibility may be influenced by the 
intestinal microbiota [30]. 
2.4.3. Host Cells 
Recent in vitro studies using a novel Stx luciferase reporter system have demonstrated induced Stx1 
and Stx2 transcription by IEC contact [17]. On the other hand, physiological levels of nitric oxide 
produced by activated IEC inhibit the bacterial SOS response and Stx2 production [31]. While this 
aspect of the innate immune response to EHEC infection appears to confer a protective effect against 
Stx-mediated damage, hydrogen peroxide production by human neutrophils has been shown to have 
the opposite effect and exacerbate Stx2 production [32]. 
EHEC colonises the follicle-associated epithelium of small intestinal Peyer’s patches ex vivo and is 
therefore likely to come into contact with underlying macrophages [33]. It has been demonstrated that 
EHEC can survive and multiply in human macrophages for up to 24 h, and enhanced expression of 
Stx1 and Stx2 was observed during this time [17,34]. Interestingly, both Stx types inhibited EHEC 
macrophage uptake but promoted intracellular survival [34]. Toxins 2011, 3                                      
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Taken together, these studies indicate that the intestinal environment affects Stx production and 
release during EHEC infection, and further research in this area will be important to gain a better 
understanding about the early events leading to HUS pathogenesis. 
3. Gb3 Expression, Stx Uptake and Intracellular Trafficking 
Stx binding and internalisation have been investigated extensively using a wide range of host cells. 
Although most of the studies have been performed on Stx1 and Stx from Shigella dysenteriae type 1 
which differs from Stx1 by a single amino acid, it is generally accepted that Stx2 follows the same 
intracellular transport route and has the same mode of action. It has emerged that Stx cytotoxicity is 
strongly associated with the amount of Gb3 expressed on the cell surface [35,36], Gb3 density, and 
association  with  cholesterol-containing  lipid  rafts  [37–39].  In  addition,  differential  Gb3  isoform 
expression with respect to fatty acid chain length, hydroxylation, and degree of saturation has been 
shown to affect Stx binding and intracellular transport [40–42]. 
3.1. Stx Transport in Sensitive Cells 
Shiga toxins have an AB5 structure with one enzymatically active A subunit non-covalently linked 
to  a  pentamer  of  B  subunits  responsible  for  Gb3  binding  [43].  After  binding  of  Stx  to  lipid  
raft-associated Gb3, Stx is internalised into early endosomes and then travels further to the trans-Golgi 
network (Figure 1). During this early stage, the Stx A subunit is cleaved by furin into an active A1 
subunit  and  an  A2  fragment  associated  with  the  B  pentamer  [44].  StxA1  still  remains  linked  to  
StxA2-B via a disulfide bond and the activated toxin complex is transported via the retrograde pathway 
to the Golgi apparatus, endoplasmic reticulum (ER) and nuclear membrane [45]. After reduction of the 
disulfide bond in the ER, StxA1 is retro-translocated into the cytoplasm where it binds to the large 
ribosomal subunit and inhibits protein synthesis by cleaving off a single adenine residue from the 28S 
rRNA [46]. While inhibition of protein synthesis in itself does not kill the host cell, it  triggers a 
ribotoxic stress response which ultimately leads to apoptosis [47]. 
3.2. Stx Transport in Resistant Cells 
Retrograde Stx transport to the ER and nucleus has been linked to cytotoxicity as toxin trafficking is 
different in Stx-resistant cells (Figure 1). In macrophages and dendritic cells, Gb3 is not associated 
with lipid rafts and Stx is transported along the endosomal/lysosomal pathway and ultimately degraded 
in lysosomes [38]. A similar mechanism of Stx inactivation has also been demonstrated for bovine 
lower crypt IEC which bind Stx1 but are resistant to cytotoxicity [48]. Cattle are a natural reservoir of 
EHEC which harmlessly colonise the distal colon [49]. Resistance of bovine intestinal epithelium to 
Stx and the absence of Gb3 on endothelium most likely contribute to the asymptomatic status of cattle 
during EHEC infection [50]. 
Apart from lysosomal degradation, Stx transport in resistant cells such as epidermoid carcinoma, 
astrocytoma, and ovarian carcinoma cells has been reported to be arrested in the Golgi apparatus. 
Cytotoxicity can be induced by addition of the differentiation agent butyrate which restores retrograde Toxins 2011, 3                                      
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transport to the ER/nucleus [42,51]. Both studies suggest that this effect is mediated via alteration of 
Gb3 fatty acid chain length. 
Figure 1. Intracellular Stx transport in resistant and sensitive cells. 
 
3.3. Stx Interaction with Human IEC and Intracellular Transport 
Human intestinal epithelium represents the first point of contact of released Stx with the host and 
furthermore acts  as  a barrier by preventing toxin  access  to  the systemic circulation.  Interestingly, 
normal  human  intestinal  epithelium  does  not  express  Gb3  or  any  other  Stx  receptor  [52–55].  In 
contrast, Gb3 expression on colonic epithelium is associated with malignancy and metastasis, and the 
potential use of Stx in cancer therapy is currently under extensive investigation [56–58].  
Accordingly, most commonly used human colon carcinoma cell lines (Caco-2, HT-29, and HCT-8) 
express Gb3 on the cell surface and are susceptible to Stx to a variable degree [54,59,60]. Treatment 
with butyrate has been reported to promote Gb3 expression and Stx sensitivity in Caco-2A and HT-29 
cells, indicating that Gb3 expression is regulated by cell maturation [59]. In contrast to these villus-like 
cell  lines,  crypt-like  colon  carcinoma-derived  T84  cells  do  virtually  not  express  Gb3  in  the  fully 
differentiated  state  and  are  resistant  to  Stx-induced  inhibition  of  protein  synthesis  and  
apoptosis [54,59]. Surprisingly, Stx1 and Stx2 are internalised by T84 cells despite the lack of Gb3 and 
activated toxin is transported to the ER [54,61]. It still remains to be determined why retrograde toxin 
transport does not result in T84 cytotoxicity, but it could be speculated that StxA1 release from the ER 
into  the  cytoplasm  is  disrupted.  This  is  supported  by  recent  studies  which  suggest  that  
retro-translocation is the rate-limiting step in Stx cytotoxicity as only 4% of StxA1 is released into the 
cytoplasm [62]. 
Stx interaction with normal  (as  opposed to  cancerous)  IEC  has  been studied by  in  vitro  organ 
culture of human intestinal mucosal biopsies, and results have indicated that Stx2 but not Stx1 causes 
damage to crypt epithelial cells [54]. As Stx access was not restricted to the mucosal biopsy surface, no 
conclusions could be drawn as to whether damage was caused by direct Stx-epithelial interaction or Toxins 2011, 3                                      
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indirectly via effects on cells in the underlying lamina propria [54]. Interestingly, recent studies have 
demonstrated a direct effect of Stx1 on IEC by enhancing galectin-3 secretion and thereby causing 
mistargeting of absorptive brush border proteins [63]. Notably, this effect could have an implication in 
EHEC-induced diarrhoea. In addition, it has been shown that Paneth cells, which are key players in the 
small intestinal innate immune defense, express Gb3 and bind Stx1 and Stx2, and the functional role of 
this interaction needs to be determined [64]. 
4. Stx Translocation across Intestinal Epithelium 
Systemic complications during EHEC infection are caused by Stx and it is assumed that Stx reaches 
its target sites (kidney and central nervous system) via the bloodstream [3]. Free Stx has not been 
detected in sera of HUS patients so far, but Stx binding to neutrophils has been demonstrated [65]. 
After Stx is released into the gut lumen it has to traverse the intestinal epithelium which forms a tight 
barrier to prevent entry of luminal contents into underlying tissue. The mechanism of this process 
remains unclear as there are no appropriate animal models available to study this aspect of EHEC 
infection. Unlike human intestinal epithelium which lacks Gb3 on its surface, Gb3 is expressed by IEC 
in the mouse distal colon [66]. In rabbits, intestinal epithelial Gb3 expression rapidly increases with 
age [67]. Human intestinal xenografts in mice have been recently used in EHEC and Stx studies and 
might provide a valuable model system in the future [55,68]. 
EHEC-induced gastroenteritis is accompanied by severe inflammation and mucosal damage in the 
caecum and ascending colon [69]. Therefore, it is likely that Stx leaks through damaged epithelium at 
later stages of infection. However, there are various possible routes of Stx translocation at earlier 
phases of infection which are described below (Figure 2). 
Figure  2.  Potential  routes  of  Stx  translocation  across  human  intestinal  epithelium.  
(a) Gb3-independent transcytosis, possibly enhanced by EHEC infection; (b) Paracellular 
transport  during  neutrophil  (PMN)  transmigration;  (c)  Induction  of  Gb3  expression  by 
EHEC infection, retrograde transport and Stx release after cell death; (d) Gb3-dependent 
translocation by Paneth cells; (e) Transcytosis by M cells. 
 
   Toxins 2011, 3                                      
 
 
632 
4.1. Stx Transcytosis by Gb3-Negative IEC 
Earlier  studies  have  demonstrated  translocation  of  purified  Stx1  and  Stx2  across  polarised 
monolayers  of  Stx-resistant  Caco-2A  and  T84  colon  carcinoma  cells.  Neither  cell  viability  nor 
epithelial barrier function was compromised indicating a transcellular pathway of translocation for 
both  Stx types  [70,71].  However,  differences  in  translocation  rates  and  directionality,  effects  of 
cellular drugs, and competition experiments indicate that Stx1 and Stx2 transcytose IEC by different 
pathways [71,72]. Transcytosis of Stx1 was further confirmed by immunoelectron microscopy which 
detected intracellular toxin in association with endosomes, Golgi, ER, and the nuclear membrane, 
but showed no association with tight junctions [61]. Stx localisation in these cellular compartments 
is  in  agreement  with  retrograde  transport  in  colon  carcinoma  cells  and  could  be  part  of  the 
translocation process. However, use of brefeldin A which disrupts the Golgi apparatus, showed no 
effect  on  Stx1  or  Stx2  translocation  indicating  that  transcytosis  is  independent  of  retrograde  
transport [71]. This is in agreement with more recent studies showing that Stx1 translocation by T84 
cells is an unsaturable, Gb3-independent process which involves actin turnover [73]. These criteria 
apply to the process of macropinocytosis, and it has recently been demonstrated that induced Src 
kinase-mediated  macropinocytosis  enhances  Stx1  uptake  and  translocation.  Interestingly,  results 
from this study have also shown that EHEC infection can trigger Src kinase activation, thereby 
suggesting a promoting role of infection in toxin translocation [74]. 
4.2. Paracellular Stx Translocation 
EHEC infection causes redistribution of intercellular tight junction proteins such as occludin and 
ZO-1, and thereby leads to decreased epithelial barrier function. These changes are initiated by type III 
secretion of the EHEC effector proteins EspF and EspFU into the host cell which trigger subsequent 
signal transduction events [75,76]. EHEC-mediated disruption of tight junctions may provide a means 
for Stx to cross the epithelial barrier and this hypothesis has been tested by infecting polarised T84 
cells  with  Stx-negative  EHEC  to  decrease  barrier  function  and  subsequently  applying  Stx1.  No 
significant difference in Stx translocation rate was observed compared with cells treated with purified 
toxin alone indicating that tight junctions of infected cells still retain their sieving function for larger 
molecules such as Stx [61]. 
Another mechanism whereby disruption of tight junctions is likely to occur during infection is by 
transmigrating  neutrophils.  Recruitment  of  neutrophils  to  infected  mucosa  is  a  prominent  feature 
observed  during  EHEC  diarrhoea,  and  elevated  neutrophil  levels  in  stools  indicate  neutrophil 
transmigration from the mucosa into the gut lumen [77–80]. This event has been simulated in vitro by 
co-incubating polarised T84 monolayers with neutrophils on the basal side and inducing neutrophil 
transmigration by adding a chemoattractant to the apical side. During the process of transmigration, 
epithelial  barrier  function  was  diminished  and  apical  to  basal  Stx1  and  Stx2  translocation  was 
enhanced. Importantly, the authors demonstrated induced neutrophil transmigration by EHEC infection 
indicating that this process might be relevant in the in vivo situation [72]. 
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4.3. Stx Uptake by Gb3-Positive IEC 
Previous  reports  have  demonstrated  that  Gb3  expression  and  Stx1  and  Stx2  cytotoxicity  on  
Gb3-positive  endothelial  cells  can  be  enhanced  by  treatment  with  butyrate,  pro-inflammatory 
cytokines or bacterial lipopolysaccharide (LPS) [81–84]. Similarly, butyrate treatment of Gb3-positive 
colon carcinoma cells results in increased Stx1 susceptibility due to enhanced Gb3 expression, but this 
does not affect Gb3-negative T84 cells [59]. The effect of bacterial LPS on Gb3 expression on human 
IEC has not been tested yet, but it could be speculated that EHEC infection induces epithelial Gb3 
expression (by LPS or other bacterial factors) and thereby leads to toxin uptake, retrograde transport 
and cell death. In addition, EHEC infection results in severe inflammation of the intestinal mucosa 
which might lead to Gb3 induction on IEC. This hypothesis has been tested by comparing Stx1/Stx2 
binding to normal and inflamed intestinal mucosa. No difference in Stx binding was detected between 
the two groups and no expression of epithelial Gb3 was observed in inflamed samples [64]. However, 
Gb3 expression and Stx binding to Paneth cells was observed in 30–60% of samples and it remains to 
be investigated whether Paneth cells might provide an entry site for Stx into underlying tissues [64]. 
4.4. Stx Translocation by M Cells 
In vitro organ culture of human intestinal biopsies has shown that EHEC adheres predominantly to 
the follicle-associated epithelium of small intestinal Peyer’s patches [33]. This area is particularly rich 
in M (microfold) cells which are specialised in uptake and translocation of antigens from the intestinal 
lumen to underlying antigen-presenting cells. Because of their transcytotic activity, M cells are often 
exploited by intestinal pathogens for invasion into underlying tissues and have also been implicated in 
translocation of bacterial toxins [85,86]. It is tempting to speculate that EHEC and/or Stx can breach 
the epithelial barrier via M cells and future research in this area is needed to test this possibility. 
5. Conclusions 
So far, only little information is available on the regulation of Stx expression and toxin transport in 
the human gut. Further research is necessary to address the influence of environmental factors in the 
human intestine on Stx production and release. In addition, appropriate experimental model systems 
need to be developed which are based on native human IEC rather than cancer-derived cell lines to 
reflect Gb3 expression patterns in healthy tissues. As it is becoming more evident that EHEC infection 
might influence Stx uptake and translocation by IEC, future studies should be performed in the context 
of infection rather than using purified Stx alone. Ultimately, a better understanding of Stx-related 
events  in  the  human  gut  is  necessary  and  important  as  it  will  lead  to  the  development  of  early 
intervention strategies against HUS. 
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